[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpTmaeMj_AJJEUiv1P0utp2hM6Vh60BRg7_7MEwmtEDQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Stallergenes Greer",[4],26,false,0,12,12904,4,[13,16,18,21,23,26,28,30],{"name":14,"count":15},"Allergy",8,{"name":17,"count":11},"Rhinitis, Allergic, Seasonal",{"name":19,"count":20},"Allergic Rhinitis",3,{"name":22,"count":20},"House Dust Mite Allergy",{"name":24,"count":25},"Asthma",2,{"name":27,"count":25},"Allergic Rhinitis Due to Grass Pollens",{"name":29,"count":25},"Allergic Rhinitis Due to House Dust Mite",{"name":31,"count":25},"Birch Pollen-Related Rhinoconjunctivitis",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,96,144,187,220,249,267,285,311,334,377,401,419,443,467,491,509,527],{"intervention":42,"totalTrials":11,"cells":43},"300 IR",{"EARLY_PHASE1":44,"PHASE1":46,"PHASE2":48,"PHASE3":50,"PHASE4":92,"NA":94},{"trials":45,"activeCount":8},[],{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52,63,72,82],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":58,"start":59,"enrollment":60,"conditions":61,"interventions":62},"NCT00418379","Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets","COMPLETED",[37],"2010-08","2011-09","2006-12",633,[14],[42,42],{"nctId":64,"briefTitle":65,"status":55,"phases":66,"primaryCompletion":67,"completion":67,"start":68,"enrollment":69,"conditions":70,"interventions":71},"NCT00955825","Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis",[37],"2009-08","2008-10",473,[27],[42],{"nctId":73,"briefTitle":74,"status":55,"phases":75,"primaryCompletion":76,"completion":76,"start":77,"enrollment":78,"conditions":79,"interventions":81},"NCT02443805","Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR",[37],"2018-06-25","2015-09-29",1607,[80,22],"Rhinitis, Allergic, Perennial",[42],{"nctId":83,"briefTitle":84,"status":55,"phases":85,"primaryCompletion":67,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":91},"NCT00803244","Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis",[37],"2010-01","2009-01",381,[90],"Primary Disease",[42],{"trials":93,"activeCount":8},[],{"trials":95,"activeCount":8},[],{"intervention":97,"totalTrials":20,"cells":98},"300 IR house dust mites allergen extract",{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":117,"PHASE4":140,"NA":142},{"trials":100,"activeCount":8},[],{"trials":102,"activeCount":8},[],{"trials":104,"activeCount":8},[105],{"nctId":106,"briefTitle":107,"status":55,"phases":108,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":114},"NCT01527188","Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model",[36],"2012-03","2012-09-19","2010-12-08",355,[29],[115,97,116],"100 IR house dust mites allergen extract","500 IR house dust mites allergen extract",{"trials":118,"activeCount":8},[119,130],{"nctId":120,"briefTitle":121,"status":122,"phases":123,"primaryCompletion":124,"completion":58,"start":125,"enrollment":126,"conditions":127,"interventions":129},"NCT01199133","Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children","TERMINATED",[37],"2011-01","2009-10",471,[128],"Allergic Rhinitis Due to Dust Mite",[97],{"nctId":131,"briefTitle":132,"status":55,"phases":133,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":139},"NCT00674700","Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis",[36,37],"2009-02","2010-02","2007-10",509,[19],[97,116],{"trials":141,"activeCount":8},[],{"trials":143,"activeCount":8},[],{"intervention":145,"totalTrials":20,"cells":146},"300 IR grass pollen allergen extract",{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":161,"PHASE3":163,"PHASE4":183,"NA":185},{"trials":148,"activeCount":8},[],{"trials":150,"activeCount":8},[151],{"nctId":152,"briefTitle":153,"status":55,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT00619827","Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract",[35],"2008-03","2007-09",89,[159],"Seasonal Allergic Rhinitis",[145],{"trials":162,"activeCount":8},[],{"trials":164,"activeCount":8},[165,176],{"nctId":166,"briefTitle":167,"status":55,"phases":168,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":172,"interventions":173},"NCT00367640","Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis",[36,37],"2005-09","2004-11",628,[14],[174,145,175],"100 IR grass pollen allergen extract","500 IR grass pollen allergen extract",{"nctId":177,"briefTitle":178,"status":55,"phases":179,"primaryCompletion":156,"completion":156,"start":59,"enrollment":180,"conditions":181,"interventions":182},"NCT00409409","Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis",[37],278,[14],[145],{"trials":184,"activeCount":8},[],{"trials":186,"activeCount":8},[],{"intervention":116,"totalTrials":20,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":204,"PHASE3":210,"PHASE4":216,"NA":218},{"trials":190,"activeCount":8},[],{"trials":192,"activeCount":8},[193],{"nctId":194,"briefTitle":195,"status":55,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":201},"NCT01919554","Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents",[35],"2013-09","2013-07",37,[29],[116,202,203],"1000 IR house dust mites allergen extract","1500 IR house dust mites allergen extract",{"trials":205,"activeCount":8},[206],{"nctId":106,"briefTitle":107,"status":55,"phases":207,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":208,"interventions":209},[36],[29],[115,97,116],{"trials":211,"activeCount":8},[212],{"nctId":131,"briefTitle":132,"status":55,"phases":213,"primaryCompletion":134,"completion":135,"start":136,"enrollment":137,"conditions":214,"interventions":215},[36,37],[19],[97,116],{"trials":217,"activeCount":8},[],{"trials":219,"activeCount":8},[],{"intervention":221,"totalTrials":222,"cells":223},"Birch pollen allergen extract",1,{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":245,"NA":247},{"trials":225,"activeCount":8},[],{"trials":227,"activeCount":8},[],{"trials":229,"activeCount":8},[],{"trials":231,"activeCount":8},[232],{"nctId":233,"briefTitle":234,"status":55,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":244},"NCT01731249","Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis",[37],"2012-07","2012-10","2010-11",574,[241,19,242,243],"Hypersensitivity","Allergic Conjunctivitis","Seasonal Allergy",[221],{"trials":246,"activeCount":8},[],{"trials":248,"activeCount":8},[],{"intervention":174,"totalTrials":222,"cells":250},{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":263,"NA":265},{"trials":252,"activeCount":8},[],{"trials":254,"activeCount":8},[],{"trials":256,"activeCount":8},[],{"trials":258,"activeCount":8},[259],{"nctId":166,"briefTitle":167,"status":55,"phases":260,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":261,"interventions":262},[36,37],[14],[174,145,175],{"trials":264,"activeCount":8},[],{"trials":266,"activeCount":8},[],{"intervention":175,"totalTrials":222,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":281,"NA":283},{"trials":270,"activeCount":8},[],{"trials":272,"activeCount":8},[],{"trials":274,"activeCount":8},[],{"trials":276,"activeCount":8},[277],{"nctId":166,"briefTitle":167,"status":55,"phases":278,"primaryCompletion":169,"completion":169,"start":170,"enrollment":171,"conditions":279,"interventions":280},[36,37],[14],[174,145,175],{"trials":282,"activeCount":8},[],{"trials":284,"activeCount":8},[],{"intervention":286,"totalTrials":222,"cells":287},"STALORAL® Birch 300 IR",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":307,"NA":309},{"trials":289,"activeCount":8},[],{"trials":291,"activeCount":8},[],{"trials":293,"activeCount":8},[],{"trials":295,"activeCount":8},[296],{"nctId":297,"briefTitle":298,"status":55,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":306},"NCT05668390","Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w\u002Fo Asthma",[37],"2025-08-06","2023-09-20",553,[304,305],"Allergic Rhinoconjunctivitis","Birch Pollen Allergy",[286],{"trials":308,"activeCount":8},[],{"trials":310,"activeCount":8},[],{"intervention":312,"totalTrials":222,"cells":313},"Staloral",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":320,"PHASE4":330,"NA":332},{"trials":315,"activeCount":8},[],{"trials":317,"activeCount":8},[],{"trials":319,"activeCount":8},[],{"trials":321,"activeCount":8},[322],{"nctId":323,"briefTitle":324,"status":55,"phases":325,"primaryCompletion":326,"completion":326,"start":136,"enrollment":327,"conditions":328,"interventions":329},"NCT00660452","A Phase III Study to Assess Efficacy and Safety of STALORAL® 300 IR Sublingual Immunotherapy (SLIT) in Asthmatic Patients Allergic to House-dust Mites",[37],"2009-07",484,[14],[312],{"trials":331,"activeCount":8},[],{"trials":333,"activeCount":8},[],{"intervention":335,"totalTrials":20,"cells":336},"rBet v 1",{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":360,"PHASE3":371,"PHASE4":373,"NA":375},{"trials":338,"activeCount":8},[],{"trials":340,"activeCount":8},[341,350],{"nctId":342,"briefTitle":343,"status":55,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":349},"NCT00889460","Safety and Tolerability Study of rBet v1 SLIT Tablets",[35],"2008-04","2007-11",55,[31,17],[335],{"nctId":351,"briefTitle":352,"status":55,"phases":353,"primaryCompletion":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT00396149","Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1",[35],"2007-03","2007-06","2006-11",57,[31,17],[335],{"trials":361,"activeCount":8},[362],{"nctId":363,"briefTitle":364,"status":55,"phases":365,"primaryCompletion":366,"completion":67,"start":68,"enrollment":367,"conditions":368,"interventions":370},"NCT00901914","Study of rBet v1 Tablets",[36],"2009-06",483,[369,17],"Birch Pollen-related Rhinoconjunctivitis",[335,335,335],{"trials":372,"activeCount":8},[],{"trials":374,"activeCount":8},[],{"trials":376,"activeCount":8},[],{"intervention":378,"totalTrials":222,"cells":379},"SLIT tablets of HDM allergen extracts, 3 different doses",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":395,"PHASE4":397,"NA":399},{"trials":381,"activeCount":8},[],{"trials":383,"activeCount":8},[],{"trials":385,"activeCount":8},[386],{"nctId":387,"briefTitle":388,"status":55,"phases":389,"primaryCompletion":390,"completion":391,"start":197,"enrollment":392,"conditions":393,"interventions":394},"NCT01930461","Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma",[36],"2015-06","2015-08",386,[24,22],[378,378,378],{"trials":396,"activeCount":8},[],{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[],{"intervention":115,"totalTrials":222,"cells":402},{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":404,"activeCount":8},[],{"trials":406,"activeCount":8},[],{"trials":408,"activeCount":8},[409],{"nctId":106,"briefTitle":107,"status":55,"phases":410,"primaryCompletion":109,"completion":110,"start":111,"enrollment":112,"conditions":411,"interventions":412},[36],[29],[115,97,116],{"trials":414,"activeCount":8},[],{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[],{"intervention":420,"totalTrials":222,"cells":421},"Subcutaneous immunotherapy - Recombinant birch pollen",{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":423,"activeCount":8},[],{"trials":425,"activeCount":8},[],{"trials":427,"activeCount":8},[428],{"nctId":429,"briefTitle":430,"status":122,"phases":431,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":436},"NCT00410930","Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients",[36],"2005-11","2002-11",160,[14],[420],{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[],{"trials":442,"activeCount":8},[],{"intervention":444,"totalTrials":222,"cells":445},"SLIT tablets of house dust mite allergen extracts",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":459,"PHASE3":461,"PHASE4":463,"NA":465},{"trials":447,"activeCount":8},[],{"trials":449,"activeCount":8},[450],{"nctId":451,"briefTitle":452,"status":55,"phases":453,"primaryCompletion":454,"completion":454,"start":455,"enrollment":456,"conditions":457,"interventions":458},"NCT01608243","Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts",[35],"2014-06","2012-05",94,[24,22],[444],{"trials":460,"activeCount":8},[],{"trials":462,"activeCount":8},[],{"trials":464,"activeCount":8},[],{"trials":466,"activeCount":8},[],{"intervention":468,"totalTrials":222,"cells":469},"Sublingual tablet of ragweed pollen allergen extract",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":483,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":471,"activeCount":8},[],{"trials":473,"activeCount":8},[474],{"nctId":475,"briefTitle":476,"status":55,"phases":477,"primaryCompletion":478,"completion":125,"start":87,"enrollment":479,"conditions":480,"interventions":482},"NCT01224834","Safety and Tolerability Study of Ragweed SLIT Tablets",[35],"2009-04",60,[17,481],"Ragweed Pollen Allergy",[468],{"trials":484,"activeCount":8},[],{"trials":486,"activeCount":8},[],{"trials":488,"activeCount":8},[],{"trials":490,"activeCount":8},[],{"intervention":202,"totalTrials":222,"cells":492},{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":494,"activeCount":8},[],{"trials":496,"activeCount":8},[497],{"nctId":194,"briefTitle":195,"status":55,"phases":498,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":499,"interventions":500},[35],[29],[116,202,203],{"trials":502,"activeCount":8},[],{"trials":504,"activeCount":8},[],{"trials":506,"activeCount":8},[],{"trials":508,"activeCount":8},[],{"intervention":203,"totalTrials":222,"cells":510},{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":525},{"trials":512,"activeCount":8},[],{"trials":514,"activeCount":8},[515],{"nctId":194,"briefTitle":195,"status":55,"phases":516,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":517,"interventions":518},[35],[29],[116,202,203],{"trials":520,"activeCount":8},[],{"trials":522,"activeCount":8},[],{"trials":524,"activeCount":8},[],{"trials":526,"activeCount":8},[],{"intervention":528,"totalTrials":222,"cells":529},"Oralair",{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":531,"activeCount":8},[],{"trials":533,"activeCount":8},[],{"trials":535,"activeCount":8},[],{"trials":537,"activeCount":8},[],{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[542],{"nctId":543,"briefTitle":544,"status":55,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT02295969","Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With\u002FWithout Conjunctivitis",[],"2017-07-03","2014-12",307,[14],[528]]